Press Room

DDL 2022

Start
Wednesday, December 07, 2022 - 09:00
End
Friday, December 09, 2022 - 09:00
Location: Scotland, UK
Booth Number: 244

Visit ɫAV’s booth atnext December 7-9 in Edinburgh and connect with one of our Inhalation Experts.


DDL – Drug Delivery to the Lungs
Stand #244

ɫAV is aspecialist integrated CDMOoffering services for drug substance, drug product intermediate and drug product for oral and inhaled solutions. When looking for a fully Integrated Solution Provider forInhalation, ɫAV offers Customized high-performanceAPIs, Particle Engineering and Formulation along with a full range of highly specialized, innovative InhalationDevices.


In Edinburgh don’t miss ɫAV’s:

#39- Evaluation of Performance of Dry Powder Inhaler Formulations by Laser Diffraction

Luís Sousa, Senior Analytical Scientist, R&D Analytical Development, Analytical Methodologies and Method Development

#48- Capsule Filling of Spray Dried Powders for Inhalation using a Drum Filling technology: From Lab to Pilot Scale

Rui Churro, Scientist, R&D Inhalation & Advanced Drug Delivery, Process Development

#51- Enhanced engineered formulations in dry powder inhalers for high dose lung delivery

Susana Saldanha, Manager, R&D Inhalation & Advanced Drug Delivery, Formulation Development

#53 - Simulation lung dissolution – fast-tracking DPI development

ɫAV scientists with Inhalation Sciences

Also in the Press Room

See All

Lisbon, Portugal – ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ɫAV’s sustainability ambitions.  ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024